U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products, March 2015

Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases.  Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives.  Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.). 

Content included in this report includes:

• emerging cellular therapies for cardiovascular and neurological diseases;
• companies and biotech firms developing novel cellular therapies;
• a prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases; and,
• a speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies.

The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention.  Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts.  Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer’s disease, ischemic stroke, Parkinson’s disease, and spinal cord injury.